Skip to main content
Zhejiang CONBA Pharmaceutical Co.,Ltd. logo

Zhejiang CONBA Pharmaceutical Co.,Ltd. — Investor Relations & Filings

Ticker · 600572 ISIN · CNE000001H86 LEI · 300300LYPEXDXC8YSI39 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 2,787 across all filing types
Latest filing 2026-06-05 Share Issue/Capital Cha…
Country CN China
Listing Shanghai Stock Exchange 600572

About Zhejiang CONBA Pharmaceutical Co.,Ltd.

https://www.conbapharm.com/

Zhejiang CONBA Pharmaceutical Co.,Ltd. specializes in the research, development, manufacturing, and marketing of a diverse range of pharmaceutical products, with a primary focus on modern Chinese medicine and chemical drugs. The company's portfolio encompasses therapeutic areas such as cardiovascular health, digestive systems, respiratory care, and urology. Notable products include its proprietary pollen preparations for prostate health and high-purity Ginkgo biloba extracts. CONBA integrates traditional botanical knowledge with advanced extraction and formulation technologies to produce standardized health solutions. Its operations span the entire value chain, including medicinal plant cultivation, active pharmaceutical ingredient production, and finished dosage manufacturing. The company serves both clinical and over-the-counter markets, emphasizing quality control and innovation in botanical medicine.

Recent filings

Filing Released Lang Actions
关于2022年股票期权激励计划限制行权期间的提示性公告
Share Issue/Capital Change Classification · 72% confidence The document is an official announcement by Zhejiang 康恩贝制药股份有限公司 disclosing details of the 2022 stock option incentive plan and a restriction period during which option holders cannot exercise. It is not a financial report or earnings release, but a notification regarding a share issuance plan (equity incentive) and restrictions on it. This fits under the category for announcements related to share issues or other capital changes (SHA).
2026-06-05 Chinese
公司2025年年度股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 91% confidence The document is titled “2025年年度股东会决议公告” and contains detailed voting results for each proposal at the Annual General Meeting (attendance statistics, vote counts and percentages for each agenda item). It is not a presentation or the full annual report; rather, it is the official announcement of shareholder vote outcomes. This clearly fits the Declaration of Voting Results & Voting Rights Announcements category.
2026-05-13 Chinese
公司第十一届董事会第十六次会议决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at the 16th meeting of the 11th Board of Directors of Zhejiang Kang En Bei Pharmaceutical Co., Ltd. It includes approvals of various reports such as the 2025 Annual Report, ESG report, internal control evaluation report, and others. It also covers decisions on asset impairment provisions, profit distribution plans, remuneration for senior management and directors, financing authorizations, guarantees for subsidiaries, and plans for the 2025 Annual General Meeting. The document contains substantive financial and operational details, including specific figures for impairment, dividends, and financing limits. The presence of the 2026 Q1 report approval also indicates it covers interim financial reporting. The document is not merely an announcement of a report publication but includes actual resolutions and financial data. Therefore, it is best classified as a Board/Management Information (MANG) filing because it primarily reports on board meeting decisions and management approvals rather than being the full annual or interim report itself. The document length (6473 characters) and content support this classification rather than a full Annual Report (10-K) or Interim Report (IR).
2026-04-22 Chinese
会计师事务所对公司内部控制的审计报告
Audit Report / Information Classification · 95% confidence The document is titled as an "Internal Control Audit Report" issued by RSM accounting firm for Zhejiang Kang En Bei Pharmaceutical Co., Ltd. It specifically mentions auditing the effectiveness of internal control over financial reporting as of December 31, 2025. The content includes the responsibilities of the company and auditors, inherent limitations of internal control, and an audit opinion on the effectiveness of internal control. The document is signed and dated April 21, 2026, by certified public accountants. The length is 3393 characters, which is relatively short but contains substantive audit opinion content rather than just an announcement or certification. This matches the definition of an Audit Report / Information (AR), which includes standalone audit reports and applied accounting principles. It is not an Annual Report (10-K) or Interim Report (IR) because it focuses solely on internal control audit, not full financial statements or comprehensive financial performance. It is not a Regulatory Filing (RNS) because it contains substantive audit content, not just certification or attestation. Therefore, the correct classification is AR with high confidence. FY 2025
2026-04-22 Chinese
康恩贝2025年内部控制评价报告
Audit Report / Information Classification · 95% confidence The document is titled '2025年度内部控制评价报告' which translates to '2025 Internal Control Evaluation Report'. It discusses the evaluation of the company's internal control effectiveness as of December 31, 2025. The content includes detailed descriptions of internal control scope, standards, defect classifications, and conclusions about the effectiveness of financial and non-financial internal controls. It is a comprehensive report on internal control evaluation, which is typically part of audit-related disclosures. The document is 4441 characters long, which is relatively short but contains substantive evaluation content rather than just an announcement or certification. It is not an annual report, earnings release, or management discussion but focuses on internal control evaluation, which aligns with an Audit Report / Information filing. Therefore, the most appropriate classification is AR (Audit Report / Information). FY 2025
2026-04-22 Chinese
关于公司2026年度银行综合授信及融资相关事项授权的公告
Capital/Financing Update Classification · 95% confidence The document is a company announcement regarding the authorization of bank comprehensive credit and financing matters for the year 2026. It details the board meeting resolutions about financing limits, authorizations for the company president to handle financing matters, and the scope of financing activities. There are no financial statements or detailed financial performance data included. The document is primarily an update on financing authorization and limits, which fits the category of Capital/Financing Update (CAP). The document length is short and it is not a report publication announcement or certification. Therefore, the appropriate classification is CAP with high confidence.
2026-04-22 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.